15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Monopar Therapeutics Inc, 10 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $95.00 to $133.00, a moderate spread. The average target of $115.82 sits 2% below the current $117.98. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.09 next quarter toward $-1.98 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Strong Buy
Strong Buy00%
Buy1091%
Hold19%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Monopar Therapeutics Inc.
As of Sep, 8 of 9 firms rate MNPR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MNPR EPS & revenue forecast
EPS · NEXT QUARTER
$-1.09
Range $-2.77 – $-0.43 · 11 analysts · +79% YoY
Next period, 11 analysts expect Monopar Therapeutics Inc to earn $-1.09 a share (range $-2.77 – $-0.43), versus $-0.61 a year earlier. Full-year consensus is $-3.01, growing to $-1.98 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 11 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $28.3M next year.
Top analysts covering Monopar Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MNPR.
#1
Keay Nakae
Chardan Capital · Rank #89
Buy
$100.00-15.2% to target
Overall win rate
43%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #169
Hold
$119.00+0.9% to target
Overall win rate
38%
+ Follow
#3
Andres Y. Maldonado
HC Wainwright & Co. · Rank #227
Buy
$125.00+6.0% to target
Overall win rate
39%
+ Follow
#4
Sean Lee
HC Wainwright & Co. · Rank #232
Buy
$40.00-66.1% to target
Overall win rate
43%
+ Follow
#5
Andreas Argyrides
Oppenheimer · Rank #242
Buy
$115.00-2.5% to target
Overall win rate
45%
+ Follow
MNPR stock forecast FAQ
What is MNPR's average 12-month price target?+
The 11 analysts with a live target average $115.82 for Monopar Therapeutics Inc over the next 12 months, ranging from a $133.00 high to a $95.00 low.
Is MNPR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 11 analyst ratings, 10 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MNPR?+
The Street-high target is $133.00 (BTIG), and the Street-low is $95.00 (Piper Sandler). The average of all 11 active targets is $115.82.
How many Wall Street analysts cover MNPR?+
11 analysts have an active rating on Monopar Therapeutics Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering MNPR?+
Among analysts who currently cover MNPR, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #89). Their current call is Buy with a $100.00 target.
What is Monopar Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.09 per share (range $-2.77 – $-0.43) across 11 analysts. Full-year EPS is projected at $-3.01, rising to $-1.98 the following year.
How much revenue is Monopar Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $28.3M next year.
Have analysts been upgrading or downgrading MNPR lately?+
As of Sep, 8 of 9 firms rate MNPR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MNPR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
